Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

CEP-701 for PH-negative Myelofibrosis

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: June 28, 2007
Last updated: June 19, 2012
Last verified: June 2012
Results First Received: April 7, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Leukemia
Intervention: Drug: CEP-701

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 6/28/2007 through 10/25/2007. All participants recruited at UT MD Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 27 participants registered, 5 participants were ineligible to participate.

Reporting Groups
CEP-701 80 mg orally twice daily for 30 days

Participant Flow:   Overall Study

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
CEP-701 80 mg orally twice daily for 30 days

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (38 to 83) 
[Units: Participants]
Female   6 
Male   16 
Region of Enrollment 
[Units: Participants]
United States   22 

  Outcome Measures

1.  Primary:   Number of Participants With Objective Response   [ Time Frame: Response assessed after each 3 cycles (cycle = 30 days) ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Srdan Verstovsek M.D./Associate Professor
Organization: The University of Texas M. D. Anderson Cancer Center
phone: 713-792-7305

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00494585     History of Changes
Other Study ID Numbers: 2007-0070
Study First Received: June 28, 2007
Results First Received: April 7, 2011
Last Updated: June 19, 2012